ROIV · ISSUER CIK 1635088
Roivant Sciences Ltd.
Between Jul 31, 2026 and Oct 28, 2026, 12 Roivant Sciences Ltd. insiders reported $0.00 of open-market purchases and $59.9M of sales on SEC Form 4.
↗12 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. 7 of 9 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$59.9MInsider selling
−$59.9MNet open-market
Oct 27, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 202618:23 | Oct 23, 2026 | ROIV | Director | A · Grant | — | +810 | 124,490 | +1% | — | ||
| Oct 27, 202618:22 | Oct 23, 2026 | ROIV | Director | F · Tax | $36.49 | −116 | 15,351 | -1% | $4K | ||
| Oct 27, 202618:22 | Oct 23, 2026 | ROIV | Director | A · Grant | — | +513 | 15,467 | +3% | — | ||
| Oct 27, 202618:21 | Oct 23, 2026 | ROIV | Director | F · Tax | $36.49 | −77 | 112,265 | -0% | $3K | ||
| Oct 27, 202618:21 | Oct 23, 2026 | ROIV | Director | A · Grant | — | +383 | 112,342 | +0% | — | ||
| Oct 22, 202618:44 | Oct 20, 2026 | ROIV | President & Immunovant CEO | S · Sell10b5-1 | $35.11 | −200,000 | 1,399,154 | -13% | −$7.0M | ||
| Oct 20, 202617:42 | Oct 16, 2026 | ROIV | President & CIO, Director | F · Tax | $33.53 | −19,976 | 18,563,884 | -0% | $670K | ||
| Oct 20, 202617:41 | Oct 16, 2026 | ROIV | CEO, Director | F · Tax | $33.53 | −34,638 | 16,549,136 | -0% | $1.2M | ||
| Oct 5, 202618:05 | Oct 1, 2026 | ROIV | Director | S · Sell10b5-1 | $36.10 | −17,750 | 14,954 | -54% | −$641K | ||
| Oct 5, 202618:05 | Oct 1, 2026 | ROIV | Director | M · Exercise10b5-1 | $4.46 | +17,750 | 32,704 | +119% | $79K | ||
| Oct 2, 202621:00 | Sep 30, 2026 | ROIV | CEO, Director | F · Tax | $36.57 | −76,171 | 16,583,774 | -0% | $2.8M | ||
| Oct 2, 202621:00 | Sep 30, 2026 | ROIV | President and Vant Chair | F · Tax | $36.57 | +40,309 | 13,495,893 | +0% | $1.5M | ||
| Oct 2, 202617:38 | Sep 30, 2026 | ROIV | President & CIO, Director | F · Tax | $36.57 | −46,879 | 18,583,860 | -0% | $1.7M | ||
| Oct 2, 202617:37 | Sep 30, 2026 | ROIV | President & Immunovant CEO | S · Sell10b5-1 | $36.62 | −200,000 | 1,599,154 | -11% | −$7.3M | ||
| Oct 2, 202617:37 | Sep 30, 2026 | ROIV | President & Immunovant CEO | M · Exercise10b5-1 | $3.85 | +200,000 | 1,799,154 | +13% | $770K | ||
| Sep 22, 202621:00 | Sep 20, 2026 | ROIV | Chief Accounting Officer | F · Tax | $39.77 | −3,880 | 106,419 | -4% | $154K | ||
| Sep 22, 202618:26 | Sep 20, 2026 | ROIV | CFO | F · Tax | $39.77 | −2,129 | 269,681 | -1% | $85K | ||
| Sep 18, 202621:00 | Sep 16, 2026 | ROIV | Director | A · Grant | — | +5,054 | 1,753,457 | +0% | — | ||
| Sep 18, 202619:12 | Sep 16, 2026 | ROIV | Director | A · Grant | — | +5,054 | 8,965,815 | +0% | — | ||
| Sep 18, 202619:06 | Sep 16, 2026 | ROIV | Director | A · Grant | — | +5,054 | 123,680 | +4% | — | ||
| Sep 18, 202619:01 | Sep 16, 2026 | ROIV | Director | A · Grant | — | +5,054 | 111,959 | +5% | — | ||
| Sep 18, 202618:57 | Sep 16, 2026 | ROIV | Director | A · Grant | — | +5,054 | 41,162 | +14% | — | ||
| Sep 18, 202618:56 | Sep 16, 2026 | ROIV | Director | A · Grant | — | +5,054 | 14,954 | +51% | — | ||
| Sep 17, 202618:43 | Sep 15, 2026 | ROIV | Director | S · Sell10b5-1 | $39.74 | −4,938 | 9,900 | -33% | −$196K | ||
| Sep 17, 202618:42 | Sep 15, 2026 | ROIV | Director | S · Sell10b5-1 | $39.74 | −5,112 | 36,108 | -12% | −$203K | ||
| Sep 14, 202621:00 | Sep 10, 2026 | ROIV | Director | F · Tax | $40.94 | −5,133 | 8,960,761 | -0% | $210K | ||
| Sep 14, 202618:42 | Sep 10, 2026 | ROIV | Director | F · Tax | $40.94 | −2,378 | 118,626 | -2% | $97K | ||
| Sep 14, 202618:34 | Sep 10, 2026 | ROIV | Director | F · Tax | $40.94 | −2,179 | 14,838 | -13% | $89K | ||
| Sep 14, 202618:29 | Sep 10, 2026 | ROIV | Director | F · Tax | $40.94 | −1,743 | 41,220 | -4% | $71K | ||
| Sep 14, 202618:25 | Sep 10, 2026 | ROIV | Director | F · Tax | $40.94 | −2,905 | 106,905 | -3% | $119K | ||
| Sep 10, 202621:00 | Sep 8, 2026 | ROIV | Director | S · Sell10b5-1 | $39.90 | −20,000 | 42,963 | -32% | −$798K | ||
| Sep 10, 202621:00 | Sep 8, 2026 | ROIV | Director | M · Exercise10b5-1 | $8.80 | +20,000 | 62,963 | +47% | $176K | ||
| Sep 1, 202621:00 | Aug 28, 2026 | ROIV | President & Immunovant CEO | S · Sell10b5-1 | $35.77 | −200,000 | 1,599,154 | -11% | −$7.2M | ||
| Sep 1, 202621:00 | Aug 28, 2026 | ROIV | President & Immunovant CEO | M · Exercise10b5-1 | $3.85 | +200,000 | 1,799,154 | +13% | $770K | ||
| Aug 24, 202621:00 | Aug 20, 2026 | ROIV | CFO | F · Tax | $36.84 | −5,749 | 271,810 | -2% | $212K | ||
| Aug 24, 202621:00 | Aug 20, 2026 | ROIV | President & Immunovant CEO | F · Tax | $36.84 | −13,909 | 1,599,154 | -1% | $512K | ||
| Aug 21, 202621:00 | Aug 21, 2026from Aug 19, 2026 | ROIV | President & CIO, Director | S · Sell | $36.88 | −335,174 | 18,630,739 | -2% | −$12.4M | ||
| Aug 21, 202621:00 | Aug 21, 2026from Aug 19, 2026 | ROIV | President & CIO, Director | M · Exercise | $3.85 | +335,174 | 18,775,495 | +2% | $1.3M | ||
| Aug 18, 202621:00 | Aug 18, 2026from Aug 14, 2026 | ROIV | President & CIO, Director | S · Sell | $36.34 | −664,826 | 18,630,739 | -3% | −$24.2M | ||
| Aug 18, 202621:00 | Aug 18, 2026from Aug 14, 2026 | ROIV | President & CIO, Director | M · Exercise | $3.85 | +664,826 | 18,662,540 | +4% | $2.6M |